All In Biotech

NDA 019270 · Sandoz

Betoptic

Betaxolol Hydrochloride · Ophthalmic

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Aug 5, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1985

Aug 30, 1985

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9

3 Phase 3, 1 recruiting

FAERS reports

325

301 serious, 37 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 31, 2023.

INDICATIONS AND USAGE Betaxolol Hydrochloride Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. It may be used alone or in combination with other anti-glaucoma drugs. In clinical studies, Betaxolol Hydrochloride Ophthalmic Solution was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. However, caution should be used in treating patients with severe reactive airway disease or a history of asthma.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 30, 1985 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
  • BETOPTIC · BETAXOLOL HYDROCHLORIDE EQ 0.5% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Betaxolol" as an intervention, any sponsor and status, largest first.

All 9 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fall58
  • dyspnoea47
  • drug ineffective37
  • asthma33
  • nausea32
  • pain31
  • limb injury30
  • wound30
  • cardiac failure congestive29
  • fatigue29
  • haemorrhage29
  • transient ischaemic attack29

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20058
20065
20076
20084
20096
20106
20116
20127
20133
20145
20156
201610
201714
201831
201945
202019
202111
202233
202327
202433
202522
202616

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 235 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.